MARKET

AVXL

AVXL

Anavex Life
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.73
+0.47
+8.94%
After Hours: 5.76 +0.04 +0.61% 19:43 10/23 EDT
OPEN
5.37
PREV CLOSE
5.26
HIGH
5.80
LOW
5.30
VOLUME
2.10M
TURNOVER
--
52 WEEK HIGH
6.31
52 WEEK LOW
2.200
MARKET CAP
344.59M
P/E (TTM)
-13.3793
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Anavex (AVXL) in Focus: Stock Moves 9.5% Higher
Anavex (AVXL) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Zacks · 10/16 13:54
Organogenesis Holdings, Anavex Life Sciences leads healthcare gainers; Vertex Pharmaceuticals, Aphria among major losers
Gainers: Organogenesis Holdings (ORGO) +22%, Anavex Life Sciences (AVXL) +16%, Precigen (PGEN) +12%, Replimune Group (REPL) +11%, Armata Pharmaceuticals (ARMP) +11%.Losers: Vertex Pharmaceuticals (VRTX) -20%, Aphria (APHA) -16%, Cyclerion Therapeutics (CYCN) -13%, Liquidia Technologies (LQDA) -9%, Arvinas (ARVN) -7%.
Seekingalpha · 10/15 15:12
Blarcamesine data from Parkinson’s disease dementia study lifts Anavex Life Sciences
Anavex Life Sciences (AVXL) jumps 15% in premarket on heavy volume, after announcing results from Phase 2 controlled trial evaluating the safety, tolerability, and efficacy of ANAVEX 2-73 (blarcamesine) in patients with
Seekingalpha · 10/15 13:08
SNBR, GRFS among premarket gainers
SPI Energy (SPI) +56% on entering agreement with Shaanxi Tongjia Automobile.Anavex Life Sciences (AVXL) +36% after completing mid-stage study of lead drug in rare brain development disorder.Organogenesis Holdings (ORGO) +27% on Q3 preliminary results.Huttig Building Products
Seekingalpha · 10/15 12:24
Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinsons Disease Dementia
Clinically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysisCompany to host conference call today at 8:30 AM ETNEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company
GlobeNewswire · 10/15 12:00
Anavex Life Sciences Announces Results From Proof Of Concept Controlled Phase 2 Clinical Trial Of ANAVEX 2-73 In Parkinson's Dementia; Saw 'Clinically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research'
Clinically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis Company to host conference call today at 8:30 AM ET NEW
Benzinga · 10/15 11:03
Anavex 2-73 And GV-971: Turning The Tide Against Alzheimer's Disease
Anti-amyloid and anti-tau drugs only slightly slow down the progression of Alzheimer's disease because misfolded amyloid and tau proteins are only two among several factors that can trigger the disease.To treat Alzheimer's disease, it is probably necessary to slow down the production of oxidants, remove those oxidants, and repair part of the damage that they cause to the brain.Anavex 2-73 and GV-971 are two drugs that do all three.Some investment in Anavex 2-73 is worth considering at this point in time.
Seekingalpha · 10/07 10:54
Anavex completes mid-stage study of lead drug in rare brain development disorder
Anavex Life Sciences (AVXL) has completed a Phase 2 clinical trial evaluating Anavex 2-73 (blarcamesine) in patients with Rett syndrome, a rare inherited neurological disorder that occurs primarily in girls
Seekingalpha · 09/10 11:44
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AVXL. Analyze the recent business situations of Anavex Life through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AVXL stock price target is 12.00 with a high estimate of 16.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 95
Institutional Holdings: 15.17M
% Owned: 25.20%
Shares Outstanding: 60.19M
TypeInstitutionsShares
Increased
21
655.96K
New
21
-107.16K
Decreased
21
330.30K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.56%
Pharmaceuticals & Medical Research
+0.69%
Key Executives
President/Chief Executive Officer/Secretary/Director
Christopher Missling
Chief Financial Officer/Treasurer
Sandra Boenisch
Independent Director
Peter Donhauser
Independent Director
Elliot Favus
Independent Director
Athanasios Skarpelos
Independent Director
Steffen Thomas
Independent Director
Claus van der Velden
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AVXL
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including drug candidates to treat Alzheimer's disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer. Its research and development pipeline includes a clinical drug candidate and various compounds in different stages of pre-clinical study. Its product pipeline also includes ANAVEX 2-73, ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. The Company's SIGMACEPTOR Discovery Platform produces small molecule drug candidates with modes of action, based on its understanding of sigma receptors. ANAVEX 1-41 is a sigma-1 agonist. ANAVEX 1066 is a mixed sigma-1/sigma-2 ligand. As of September 30, 2016, the Company had not generated any revenues from its operations.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Anavex Life Sciences Corp stock information, including NASDAQ:AVXL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVXL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVXL stock methods without spending real money on the virtual paper trading platform.